|

Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers

RECRUITINGN/ASponsored by Universitair Ziekenhuis Brussel
Actively Recruiting
PhaseN/A
SponsorUniversitair Ziekenhuis Brussel
Started2026-05
Est. completion2028-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07359742

Summary

Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* ≥18y
* Chronic liver disease: alcohol, metabolic dysfunction associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease and hemochromatosis

Exclusion Criteria:

* \<18y
* Acute hepatitis
* Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.

Conditions3

Chronic Liver Disease (CLD)Fibrosis of LiverLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.